ArticleMikrochimica acta2026
An integrated electrochemical microfluidic chip for simultaneous detection of uric acid and interleukin-6.
Article in Mikrochimica acta, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
In gout progression, uric acid (UA) accumulation triggers crystal deposition, while interleukin-6 (IL-6) drives the subsequent inflammatory flares. Therefore, monitoring both UA and IL-6 is important for gout management. In this study, for the first time a microfluidic electrochemical system (MES) has been developed to simultaneously detect UA and IL-6 levels in blood. The MES consists of a multilayer microfluidic chip that incorporates a plasma separation module and two screen-printed electrochemical (SPE) sensors, integrated with a wireless potentiostat for real-time data analysis. The working electrode (WE) of one SPE was modified with uricase and hydrophilic fumed nano-silica (FSiO₂) for UA sensing, and the WE of the other SPE was modified with gold nanoparticle-reduced graphene oxide (Au NPs/rGO) composites and antibodies for IL-6 sensing. The MES demonstrated excellent analytical performance for the simultaneous detection of UA and IL-6 in human blood, featuring high selectivity, broad linear ranges (10-1000 µM for UA and 0.001-100 ng/mL for IL-6), robust stability, and strong concordance with reference methods (R² > 0.95). This study provides a proof-of-concept platform for gout-related biomarker determination and offers a new strategy for the development of multi-biomarker electroanalytical devices.
Indexed as
Identifiers
41954823What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.